Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Markers of dispute.

Literature DB >> 19966757

Markers of dispute.

Virginia Hughes.

Abstract

Mesh：

Substances：

Year: 2009 PMID： 19966757 DOI： 10.1038/nm1209-1339

Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440

× No keyword cloud information.

10 in total

1. POINT: EPCA-2: a promising new serum biomarker for prostatic carcinoma?

Authors: Eleftherios P Diamandis
Journal: Clin Biochem Date: 2007-09-19 Impact factor: 3.281

2. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.

Authors: T A Stamey; N Yang; A R Hay; J E McNeal; F S Freiha; E Redwine
Journal: N Engl J Med Date: 1987-10-08 Impact factor: 91.245

3. The early detection of prostate carcinoma with prostate specific antigen: the Washington University experience.

Authors: D S Smith; P A Humphrey; W J Catalona
Journal: Cancer Date: 1997-11-01 Impact factor: 6.860

4. Screening and prostate-cancer mortality in a randomized European study.

Authors: Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Antonio Berenguer; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Bert G Blijenberg; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal: N Engl J Med Date: 2009-03-18 Impact factor: 91.245

5. Mortality results from a randomized prostate-cancer screening trial.

Authors: Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal: N Engl J Med Date: 2009-03-18 Impact factor: 91.245

6. Prostate cancer screening: what we know and what we need to know.

Authors: B S Kramer; M L Brown; P C Prorok; A L Potosky; J K Gohagan
Journal: Ann Intern Med Date: 1993-11-01 Impact factor: 25.391

7. Rethinking screening for breast cancer and prostate cancer.

Authors: Laura Esserman; Yiwey Shieh; Ian Thompson
Journal: JAMA Date: 2009-10-21 Impact factor: 56.272

8. EPCA-2: a highly specific serum marker for prostate cancer.

Authors: Eddy S Leman; Grant W Cannon; Bruce J Trock; Lori J Sokoll; Daniel W Chan; Leslie Mangold; Alan W Partin; Robert H Getzenberg
Journal: Urology Date: 2007-04 Impact factor: 2.649

9. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers.

Authors: Shahrokh F Shariat; Jose A Karam; Jochen Walz; Claus G Roehrborn; Francesco Montorsi; Vitaly Margulis; Fred Saad; Kevin M Slawin; Pierre I Karakiewicz
Journal: Clin Cancer Res Date: 2008-06-15 Impact factor: 12.531

10. Identification of nuclear matrix proteins in the cancer and normal rat prostate.

Authors: R H Getzenberg; K J Pienta; E Y Huang; D S Coffey
Journal: Cancer Res Date: 1991-12-15 Impact factor: 12.701

10 in total

5 in total

Markers of dispute.

1. POINT: EPCA-2: a promising new serum biomarker for prostatic carcinoma?

2. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.

3. The early detection of prostate carcinoma with prostate specific antigen: the Washington University experience.

4. Screening and prostate-cancer mortality in a randomized European study.

5. Mortality results from a randomized prostate-cancer screening trial.

6. Prostate cancer screening: what we know and what we need to know.

7. Rethinking screening for breast cancer and prostate cancer.

8. EPCA-2: a highly specific serum marker for prostate cancer.

9. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers.

10. Identification of nuclear matrix proteins in the cancer and normal rat prostate.

1. Cholesterol sulfate imaging in human prostate cancer tissue by desorption electrospray ionization mass spectrometry.

2. Cancer biomarkers: can we turn recent failures into success?

3. Ribonuclease 4 is associated with aggressiveness and progression of prostate cancer.

Review 4. Molecular signatures from omics data: from chaos to consensus.

5. Multi-omic network signatures of disease.